These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37915245)

  • 1. Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease.
    Ariz M; Martínez M; Alvarez I; Fernández-Seara MA; Castellanos G; ; Pastor P; Pastor MA; Ortiz de Solórzano C
    J Magn Reson Imaging; 2024 Aug; 60(2):534-547. PubMed ID: 37915245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosing Parkinson's disease by combining neuromelanin and iron imaging features using an automated midbrain template approach.
    Jokar M; Jin Z; Huang P; Wang Y; Zhang Y; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Min J; Liu F; Chen S; He N; Haacke EM; Yan F
    Neuroimage; 2023 Feb; 266():119814. PubMed ID: 36528314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging the Nigrosome 1 in the substantia nigra using susceptibility weighted imaging and quantitative susceptibility mapping: An application to Parkinson's disease.
    Cheng Z; He N; Huang P; Li Y; Tang R; Sethi SK; Ghassaban K; Yerramsetty KK; Palutla VK; Chen S; Yan F; Haacke EM
    Neuroimage Clin; 2020; 25():102103. PubMed ID: 31869769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI.
    Schwarz ST; Mougin O; Xing Y; Blazejewska A; Bajaj N; Auer DP; Gowland P
    Neuroimage Clin; 2018; 19():683-689. PubMed ID: 29872633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of a high-spatial-resolution voxelwise analysis of neuromelanin-sensitive imaging in early-stage idiopathic Parkinson's disease.
    Seong M; Park S; Sung YH; Kim EY
    BMC Med Imaging; 2023 May; 23(1):64. PubMed ID: 37202720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal assessment of nigrosomal degeneration in Parkinson's disease.
    Langley J; Huddleston DE; Crosson B; Song DD; Factor SA; Hu X
    Parkinsonism Relat Disord; 2020 Nov; 80():102-107. PubMed ID: 32979784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging evaluation of nigrosome 1 and neuromelanin can assist Parkinson's disease diagnosis, but requires an expert neuroradiologist.
    De Pietro Franco Zorzenon C; Almeida Antônio Bienes GH; Duarte Alves E; Tobaru Tibana LA; Carrete Júnior H; Ballalai Ferraz H
    Parkinsonism Relat Disord; 2021 Feb; 83():8-12. PubMed ID: 33418131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial for "Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease".
    Reyes SC; Shahraki T; Soman S
    J Magn Reson Imaging; 2024 Aug; 60(2):548-549. PubMed ID: 37915261
    [No Abstract]   [Full Text] [Related]  

  • 13. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early-stage Parkinson's disease: Abnormal nigrosome 1 and 2 revealed by a voxelwise analysis of neuromelanin-sensitive MRI.
    Sung YH; Noh Y; Kim EY
    Hum Brain Mapp; 2021 Jun; 42(9):2823-2832. PubMed ID: 33751680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson's disease.
    Martínez M; Ariz M; Alvarez I; Castellanos G; Aguilar M; Hernández-Vara J; Caballol N; Garrido A; Bayés À; Vilas D; Marti MJ; ; Pastor P; de Solórzano CO; Pastor MA
    NPJ Parkinsons Dis; 2023 Apr; 9(1):62. PubMed ID: 37061532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI).
    Nam Y; Gho SM; Kim DH; Kim EY; Lee J
    J Magn Reson Imaging; 2017 Aug; 46(2):528-536. PubMed ID: 27859983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study.
    Safai A; Prasad S; Chougule T; Saini J; Pal PK; Ingalhalikar M
    Hum Brain Mapp; 2020 Apr; 41(5):1323-1333. PubMed ID: 31778276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing Nigrosome-1 Sign Identification via Interpretable AI using True Susceptibility Weighted Imaging.
    Wang C; He N; Zhang Y; Li Y; Huang P; Liu Y; Jin Z; Cheng Z; Liu Y; Wang Y; Zhang C; Haacke EM; Chen S; Yan F; Yang G
    J Magn Reson Imaging; 2024 Nov; 60(5):1904-1915. PubMed ID: 38236577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.